Timing of Complementary Feeding in Preterm Infants and Prevalence of Overweight and Obesity: A Randomized Clinical

Karin M Vissers1,2, Edith J M Feskens3, Johannes B van Goudoever2

  • 1Department of Pediatrics, Hospital Gelderse Vallei, Ede, the Netherlands.

JAMA Network Open
|April 30, 2025
PubMed

Insights

Introducing complementary foods between 12 and 17 weeks corrected age did not impact overweight and obesity rates in preterm infants by age 2. This study provides key insights for infant feeding guidelines.

Area of Science:

  • Neonatology
  • Pediatric Nutrition
  • Growth and Development

Background:

  • Initiating complementary feeding in preterm infants is critical for growth and preventing long-term health issues like overweight.
  • Current guidelines for complementary feeding in preterm infants are lacking.

Purpose of the Study:

  • To investigate the impact of initiating complementary feeding at corrected age 12 weeks versus 17 weeks on overweight and obesity prevalence at corrected age 2 years in preterm infants.

Main Methods:

  • A multicenter randomized clinical trial involving preterm infants (gestational age 30-36 weeks) and a reference group of full-term infants.
  • Preterm infants were randomized to start complementary feeding at 12 weeks (early group) or 17 weeks (late group) corrected age.
  • Primary outcome was overweight and obesity prevalence at corrected age 2 years; secondary outcomes included growth parameters and neurodevelopment.

Main Results:

  • Overweight prevalence at 2 years was 6.0% in the early group and 5.5% in the late group. Obesity prevalence was 1.7% and 1.8%, respectively.
  • No significant difference in overweight or obesity prevalence was observed between the early and late complementary feeding groups.
  • The full-term reference group exhibited higher rates of overweight (9.0%) and obesity (3.5%) compared to the preterm groups.

Conclusions:

  • Initiating complementary feeding between 12 and 17 weeks corrected age does not influence the prevalence of overweight and obesity at 2 years in preterm infants.
  • These findings suggest that the timing within this window may not be a critical factor for preventing later overweight and obesity in this population.
  • Further research may be needed to establish optimal feeding guidelines for preterm infants.
Abstract

Related Concept Videos

Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Parentral Nutrition: Centeral and Peripheral Parental Nutrition01:27

Parentral Nutrition: Centeral and Peripheral Parental Nutrition

Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...